General
Preferred name
ZOTIRACICLIB
Synonyms
TG-02 ()
TG02, TG-02 ()
SB-1317 ()
TG02 ()
SB1317, cmpd 26h ()
TG-02 hydrochloride ()
SB1317 hydrochloride (937270-47-8(free base)) ()
TG-02 (SB1317) ()
(E/Z)-Zotiraciclib ()
(E/Z)-Zotiraciclib (hydrochloride) ()
SB1317 ()
(E/Z)-TG02 ()
(E/Z)-SB1317 ()
(E/Z)-TG02 (hydrochloride) ()
(E/Z)-SB1317 (hydrochloride) ()
SB1317 (TG02) ()
SB1317 hydrochloride (1204918-72-8(free base)) ()
SB-1317 FREE BASE ()
EX45 ()
EX 45 ()
SB-1317 ()
P&D ID
PD012633
CAS
937270-47-8
1204918-72-8
1321626-25-8
Tags
available
drug candidate
Drug indication
Anaplastic astrocytoma
Chronic lymphocytic leukemia
Recurrent glioblastoma
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Zotiraciclib (TG02) is an orally active multi-kinase inhibitor, with a unique activity profile against CDKs, JAK2 and FLT3 . Like it is a small molecule macrocycle. TG02 was rationally designed to simultaneously inhibit several key signalling pathways, with the aim of maximising anti-cancer efficacy. It is being investigated for its anti-leukemic potential .
The compound is administered as the citrate salt. (GtoPdb)
DESCRIPTION (E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, JAK2 and FLT3 with IC50s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer[1][2].
DESCRIPTION (E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor[1].
PRICE 162
DESCRIPTION SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM). (TargetMol Bioactive Compound Library)
Cell lines
8
Organisms
0
Compound Sets
18
AdooQ Bioactive Compound Library
A11962
Cayman Chemical Bioactives
26817
CDK inhibitor database (CDKiDB)
ChEMBL Drugs
CHEMBL1944698
Clinical kinase drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB16656
DrugMAP
DMZFIGQ
EU-OPENSCREEN Bioactive Compound Library
EOS101788
Guide to Pharmacology
9095
JUMP-Target 1 Compound Set
16739650
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1944698
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL1944698
MedChem Express Bioactive Compound Library
HY-15163
HY-15166
HY-15166A
ReFrame library
Selleckchem Bioactive Compound Library
sb1317-tg02
TargetMol Bioactive Compound Library
T4227
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
372.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
0
Ring Count
4
Aromatic Ring Count
3
cLogP
4.66
TPSA
50.28
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
18.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
CDK1,CDK2,CDK7,CDK9,JAK2,FLT3
Target
CDK2
FLT3
JAK2
CDK1, CDK2, CDK7, CDK9, FLT3, JAK2
CDK9
CDK
JAK
FLT3,JAK
MOA
CDK inhibitor
FLT inhibitor
JAK inhibitor
CDK inhibitor, FLT3 inhibitor, JAK inhibitor
Pathway
Angiogenesis
Cell Cycle/Checkpoint
Chromatin/Epigenetic
JAK/STAT Signaling
Stem Cells
Tyrosine Kinase/Adaptors
Cell Cycle/DNA Damage
Epigenetics
Protein Tyrosine Kinase/RTK
Stem Cell/Wnt
Source data